Incyte (INCY) Net Cash Flow (2010 - 2026)
Incyte (INCY) reported Net Cash Flow of $366.0 million for Q1 2026, up 43.81% on a YoY basis from $254.5 million in Q1 2025, and down 43.14% quarter-over-quarter from $643.6 million in Q4 2025.
Incyte (INCY) Net Cash Flow (2010 - 2026) Analysis & Trends
Incyte has reported Net Cash Flow for 17 years, with the latest figure at $366.0 million in Q1 2026.
- For the quarter ending Q1 2026, Net Cash Flow rose 43.81% year-over-year to $366.0 million; the trailing twelve-month figure through Mar 2026 stood at $1.5 billion (up 208.24% YoY), and the FY2025 full-year result was $1.4 billion, up 192.36% from the prior year.
- Net Cash Flow for Q1 2026 stood at $366.0 million, down from $643.6 million in the prior quarter.
- The five-year high for Net Cash Flow was $643.6 million in Q4 2025, with the low at -$2.4 billion in Q2 2024.
- Historically, Net Cash Flow has averaged $82.9 million across 5 years, with a median of $253.7 million in 2022.
- The largest YoY upside for Net Cash Flow was 6016.68% in 2024 against a maximum downside of 856.15% in 2024.
- Incyte's Net Cash Flow stood at $260.3 million in 2022, then plunged by 102.47% to -$6.4 million in 2023, then surged by 6016.68% to $380.1 million in 2024, then surged by 69.31% to $643.6 million in 2025, then tumbled by 43.14% to $366.0 million in 2026.
- The last three Net Cash Flow figures came in at $366.0 million (Q1 2026), $643.6 million (Q4 2025), and $499.2 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Cash Flow (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | 2.44 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 625.70 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | - |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -2.44 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 457.40 Mn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | 664,983.53 |
| 10 | Incyte | 19.62 Bn | 15.60 Bn | 1.17 Bn | 365.97 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 365.97 Mn |
| Mar 31, 2026 | 365.97 Mn |
| Dec 31, 2025 | 643.62 Mn |
| Dec 31, 2025 | 643.62 Mn |
| Sep 30, 2025 | 499.20 Mn |
| Sep 30, 2025 | 499.20 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Jun 30, 2025 | 14.62 Mn |
| Mar 31, 2025 | 254.49 Mn |
| Mar 31, 2025 | 254.49 Mn |
| Dec 31, 2024 | 380.15 Mn |
| Dec 31, 2024 | 380.15 Mn |
| Sep 30, 2024 | 316.79 Mn |
| Sep 30, 2024 | 316.79 Mn |
| Jun 30, 2024 | -2.36 Bn |
| Jun 30, 2024 | -2.36 Bn |
| Mar 31, 2024 | 133.29 Mn |
| Mar 31, 2024 | 133.29 Mn |
| Dec 31, 2023 | -6.43 Mn |
| Dec 31, 2023 | -6.43 Mn |